AZD9592 + sabestomig

AZD9592 + sabestomig is an investigational combination therapy for advanced solid tumors. **AZD9592** is a bispecific antibody-drug conjugate (ADC) that targets both epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET), delivering a topoisomerase I inhibitor (TOP1i) payload to tumor cells expressing these receptors, causing double-stranded DNA breaks and tumor cell death. **Sabestomig** is a monoclonal antibody immunotherapy targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), a checkpoint inhibitor pathway, aiming to enhance anti-tumor immune responses by modulating T cell activity. The combination seeks to improve efficacy by coupling direct tumor cell cytotoxicity (ADC) and immune checkpoint inhibition (immunotherapy) for patients with advanced solid tumors, particularly after limited response to traditional checkpoint inhibition[2][4][5][6].